GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Net Income Including Noncontrolling Interests

PBM (Psyence Biomedical) Net Income Including Noncontrolling Interests : $-46.59 Mil (TTM As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Psyence Biomedical Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Psyence Biomedical's Net Income Including Noncontrolling Interests for the six months ended in Sep. 2024 was $2.96 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 was $-46.59 Mil.

Psyence Biomedical Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Psyence Biomedical's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Psyence Biomedical Net Income Including Noncontrolling Interests Chart

Psyence Biomedical Annual Data
Trend Mar21 Mar22 Mar23 Mar24
Net Income Including Noncontrolling Interests
- -1.86 -3.21 -51.16

Psyence Biomedical Semi-Annual Data
Mar21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial -0.64 -2.57 -1.61 -49.55 2.96

Psyence Biomedical Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-46.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psyence Biomedical Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Psyence Biomedical's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Psyence Biomedical Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Psyence Biomedical Ltd (NAS:PBM) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
GRI ZVSA QRON TNFA SPRB ALZN KTTA SCNI CDT QLGN VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
121 Richmond Street West, Penthouse Suite 1300, Toronto, ON, CAN, M5H 2K1
Website
https://www.psyence.com
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.